[Isolated systolic hypertension. An independent disease].
Hypertension can be classified based on certain criteria, such as severity, existence of specific end-organ damage, or the dominant blood pressure subphenotype so that isolated diastolic hypertension (IDH), mixed systolic-diastolic hypertension (SDH), and isolated systolic hypertensive (ISH) states can be defined. The FRAMINGHAM study was the first to demonstrate a continuous increase of systolic blood pressure with age and a peak of diastolic pressure between 55 and 65 years of age. This results not only in a high prevalence of hypertension of approximately 50-80% beyond the age of 60 but also in a disproportionately high increase in isolated systolic hypertension. ISH develops either as a new condition mostly from the group of primary high-normal blood pressure or secondly through burnout of existing systolic-diastolic hypertension with highly progressive vascular ageing.The pathophysiological background lies in remodeling processes in the macrovascular and microvascular compartments with stiffening of conduit and peripheral arterial vessels. In clinical practice these processes are easy to measure by determining pulse wave velocity (PWV), the augmentation index, and pulse pressure. These parameters are closely related to cardiovascular and cerebrovascular morbidity and mortality ISH is not only a hypertension subphenotype but often indicates significant organ damage or may even be considered to be a secondary form of hypertension characterized by remodeled and stiffened arterial vessel walls and this condition is difficult to treat. It appears therefore that ISH warrants special therapeutic strategies with a focus on antiproliferative, antistiffening, anti-atherosclerotic, and vasodilating actions. As a result of the available data from the results of treatment studies it appears that renin-angiotensin system (RAS) blockers and calcium channel blockers (CCBs) are the preferred drugs for treatment of this condition.
Scholze
J
J
Medizinische Poliklinik, Charité Universitätsmedizin Berlin, Luisenstr. 11-13, 10117, Berlin. juergen.scholze@charite.de
D000367:Age Factors; D000368:Aged; D001783:Blood Flow Velocity / Q000502:physiology; D001794:Blood Pressure / Q000502:physiology; D002423:Cause of Death; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D008833:Microcirculation / Q000502:physiology; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D012016:Reference Values; D012307:Risk Factors; D015996:Survival Rate; D013599:Systole / Q000502:physiology; D014664:Vasodilation / Q000502:physiology